Morgan Bayer

Paul B. Renz, DO, discussed the ideal uses of MR-LINAC in pancreatic, prostate, liver, head and neck, and rectal cancers.

Data from the phase 2 ROME trial were presented by Andrea Botticelli, MD, during the ESMO Targeted Anticancer Therapies Congress 2025.

Findings from the TROPION-Lung04 study were presented at the ESMO Targeted Anticancer Therapies Congress 2025 in March.

Experts developed consensus recommendations through the modified Delphi process for metastatic prostate cancer management during the 2024 US Prostate Cancer Conference.

Fewer prior therapies with liso-cel in chronic lymphocytic leukemia showed improved overall response rate in TRANSCEND-CLL-004 analysis.

Chemotherapy/Pembrolizumab SC shows noninferior to SOC in NSCLC, expert insights on advances with CAR T-cells, and a full approval for gastric cancer.

The FDA approved agents in MIBC and neuroendocrine tumors and amivantamab/lazertinib continues to shine in NSCLC.

Survivorship Care is highlighted, providing emotional, physical, and practical care for patients, along with other positive data to be aware of.

Positive data and developments to be aware of in AML, breast cancer, PDAC, and NMIBC.

This week's Targeted Pulse highlights immunotherapy’s success in triple-negative breast cancer and key FDA actions shaping treatment advancements.

Forward steps are being made in HNSCC, and the first patient with MDS has been treated with iadademstat/azacitidine.

Two denosumab biosimilars have gained FDA approvals across multiple indications.

The FDA advances in multiple cancer types, and researchers assess potential impacts of funding freezes on cancer research.

FDA approves vimseltinib for tenosynovial giant cell tumor and a triplet for R/R LBCL, plus the latest from ASCO GU 2025.

Third-line enfortumab vedotin improved outcomes in metastatic urothelial carcinoma, per real-world data from the EV-301 trial.

The FDA makes furthering moves in SCLC, ovarian, and breast cancers, and the value of remote clinical pharmacists is explored in community oncology.

G-CSF plus docetaxel modification allowed almost all patients with mHSPC to receive an efficacious dose of docetaxel plus darolutamide/ADT.

One concern with bispecific antibody therapies in community settings is managing adverse events, with emerging patterns guiding management strategies.

The FDA made strides in R/R T-cell lymphoma and breast cancer. An AI tool aids pathologists and other positive updates in gastric cancer and NSCLC.

Aspirin reduced recurrence by 50% in PIK3CA-mutated colorectal cancer, the DCISionRT test earned FDA breakthrough status for predicting radiotherapy benefit in DCIS, and nivolumab plus chemotherapy sustained efficacy in gastric/GEJ/esophageal cancers. We also provide an overview of key abstracts from ASCO GI and molecular oncology and how it is changing care.

The LumiSystem detection tool is now commercially available in the US.

Pathologists supported by a new artificial intelligence tool outperformed Standard of Care/Gold standard in determining between HER2 0 from 1+ - low expressing cases.

A pooled analysis of sunvozertinib in EGFR TKI-resistant NSCLC showed promising antitumor activity and favorable safety, achieving a 27.5% objective response rate.

Dato-DXd for breast cancer and sotorasib/panitumumab for CRC have gained FDA approval and a new drug is under FDA review for BCG-unresponsive, high-risk NMIBC. We also explore the controversy surrounding CDK4/6 inhibitors in adjuvant breast cancer therapy and discuss the MARIPOSA data for EGFR-mutated NSCLC.

Nivolumab demonstrated superior efficacy in LA-HNSCC, whereas the combination of durvalumab and cetuximab showed limited success. Abenacianine received fast track designation for lung cancer surgery, the combination of amivantamab and Lazertinib showed OS improvement in NSCLC, and sunvozertinib has been granted priority review status for NSCLC.

Ticiana Leal, MD, discussed the case of a 73-Year-Old woman with progressive extensive-stage small cell lung cancer.

Bispecific antibody therapy is transforming cancer treatment, especially in multiple myeloma, with ongoing studies exploring early-line and maintenance use.

In 2024, lung cancer treatment saw significant strides, including the approval of ensartinib for ALK-positive NSCLC and tarlatamab for SCLC. Advances also included December approvals, promising ADC research in NSCLC, and potential future FDA approvals under consideration.

The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on treatment choices for gastric adenocarcinoma and ctDNA monitoring and clearing in HER2-positive breast cancer.